SEC EDGARJUN 261 min read$ILMN

Davies Scott M sold $111K of ILMN

Davies Scott M (Chief Legal Officer) sold 615 shares of ILLUMINA, INC. (ILMN) at $180.00 ($0.11M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Davies Scott M

Published Jun 26, 2026, 1:41 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jun 26, 2026, 2:02 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$ILMN

Neutral

high confidence

Mentioned

$ILMN

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$ILMNNeutralLow

Why it matters

The newest fact is the specific sale: 615 shares at $180/share ($110,700 total) by the Chief Legal Officer on 2026-06-25 under a 10b5-1 plan.

Market read

Primarily useful for sentiment/positioning checks; it does not introduce new operational, financial, or regulatory information.

What to watch

The transaction size is small relative to typical institutional flows, and the pre-arranged plan reduces interpretability versus discretionary selling.

Relevance 3/10Novelty 2/10Timing: after-hours/filing update on 2026-06-25 (filed 2026-06-25T21:41:44-04:00)

Background

This is an SEC Form 4 insider transaction disclosure for Illumina, Inc. (ILMN).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ILMNNeutralHigh confidence

Context

Illumina Form 4 shows CLO Davies Scott M sold 615 shares at $180 on 2026-06-25 under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any impact is likely limited to intraday sentiment around the filing.

Evidence & confidence

The filing is an open-market sale by an officer under a pre-arranged 10b5-1 plan, with modest share count and no accompanying company-specific operational/regulatory news.

Market effects

Sector

No direct read-through to biotech/genomics sector fundamentals; this is company-specific insider transaction data.

Regional

Minimal; US-listed large-cap insider sale with no broader market linkage.

Global

None expected beyond routine sentiment monitoring for ILMN.

Counterpoint

What could challenge this read

Even 10b5-1 sales can coincide with private information, so traders may still watch for follow-on disclosures or unusual volume/price action.

Key entities

issuer
Illumina, Inc.
Subject of the Form 4 insider transaction disclosure.
insider
Davies Scott M
Chief Legal Officer who sold 615 shares under a pre-arranged 10b5-1 plan.

Read at source ← All news

OCT 26

$MRNAMed

Moderna’s Rally May Have Run Out of Steam. Here’s What to Watch Next

Moderna (MRNA) shares fell 20% after leaked trial data for its melanoma vaccine, despite analysts calling results 'strong.' The drop may signal the end of its 700% year-to-date rally. Merck (MRK), partnering on the vaccine, saw minimal impact. Analysts expect Merck to report strong earnings. BioNTech (BNTX) and Illumina (ILMN) are also mentioned.

aol.com3 min

OCT 13

$ILMNMed

Illumina Launches $1.0 Billion Unsecured Commercial Paper Program; Signs Dealer Agreements

Illumina established a $1.0 billion unsecured commercial paper program for general corporate purposes. The program allows short-term notes with maturities up to 397 days. A national bank will serve as the issuing and paying agent, with three dealers initially participating. No notes were outstanding as of the filing date.

tradingview.com1 min

OCT 5

$ILMNMed

Illumina (ILMN) Shares Skyrocket, What You Need To Know

Illumina (ILMN) shares rose 7.7% after analysts raised price targets, citing expected clinical sales growth and AI applications. The stock closed at $293.84, up 7.6%. Illumina's shares have seen significant volatility, with a 22.4% gain last year on strong earnings. The company has raised its full-year EPS guidance to $4.70. ILMN is up 119% YTD, reaching a 52-week high.

financialcontent.com2 min

SEP 24

$ILMNHighAI 8/10

Illumina Soars to New High After Index Win

Illumina (ILMN) shares hit a 52-week high after being added to the S&P 500 Equal Weighted Index. The company announced a $300M note offering, strong earnings, and raised full-year guidance. Analysts increased price targets, citing sustainable earnings and clinical sequencing demand. The stock's rise is driven by index inclusion, debt refinancing, and upgraded guidance, with future growth expected from its sequencer business model.

tipranks.com2 min

SEP 23

$GRALMed

This test screens for 50 cancers - but whether Medicare and other health insurers will cover it hinges on FDA approval

Grail's Galleri test, which screens for 50 cancers, is under FDA review for approval. A major study failed to prove it detects later-stage cancers, causing skepticism among doctors. Grail's stock dropped 50% on the news but has since rebounded. FDA approval could lead to insurance coverage and impact competitors like Caris Life Sciences and Guardant Health.

morningstar.com6 min

SEP 18